Amarin Corp Plcuk (AMRN) Amortizatization of Intangibles (2020 - 2026)
Amarin Corp Plc\Uk (AMRN) posted quarterly Amortizatization of Intangibles of $470000.0 for Q2 2026, down 51.7% year-over-year from $973000.0 in Q2 2025, and down 11.65% quarter-over-quarter from $532000.0 in Q1 2026.
Amarin Corp Plcuk (AMRN) Amortizatization of Intangibles (2020 - 2026) Analysis & Trends
Amarin Corp Plc\Uk (AMRN) has reported Amortizatization of Intangibles for 7 consecutive years, with $470000.0 the latest figure, recorded in Q2 2026.
- In Q2 2026, Amortizatization of Intangibles fell 51.7% year-over-year to $470000.0; the TTM figure through Jun 2026 stood at $2.5 million (down 52.46% YoY), while the FY2025 annual figure was $3.6 million, down 36.36% from the prior year.
- Amortizatization of Intangibles slipped to $470000.0 in Q2 2026 per AMRN's latest filing, from $532000.0 in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $1.6 million in Q4 2024 and bottomed at -$374000.0 in Q1 2022.
- Historically, Amortizatization of Intangibles has averaged $755555.6 across 5 years, with a median of $868500.0 in 2023.
- Annual changes were most pronounced in 2023 — Amortizatization of Intangibles soared 570.65% — and 2025, when it tumbled 59.96%.
- Amarin Corp Plc\Uk's Amortizatization of Intangibles stood at $284000.0 in 2022, then surged by 291.9% to $1.1 million in 2023, then surged by 40.7% to $1.6 million in 2024, then sank by 59.96% to $627000.0 in 2025, then dropped by 25.04% to $470000.0 in 2026.
- Business Quant data shows AMRN's Amortizatization of Intangibles at $470000.0 in Q2 2026, $532000.0 in Q1 2026, and $627000.0 in Q4 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | - |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | - |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 984.00 Mn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | - |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 600.00 Mn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | - |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Amarin Corp Plcuk | 5.86 Bn | 5.54 Bn | 14.99 Mn | 470,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 470,000.00 |
| Jun 30, 2026 | 470,000.00 |
| Mar 31, 2026 | 532,000.00 |
| Mar 31, 2026 | 532,000.00 |
| Dec 31, 2025 | 627,000.00 |
| Dec 31, 2025 | 627,000.00 |
| Sep 30, 2025 | 830,000.00 |
| Sep 30, 2025 | 830,000.00 |
| Jun 30, 2025 | 973,000.00 |
| Jun 30, 2025 | 973,000.00 |
| Mar 31, 2025 | 1.22 Mn |
| Mar 31, 2025 | 1.22 Mn |
| Dec 31, 2024 | 1.57 Mn |
| Dec 31, 2024 | 1.57 Mn |
| Sep 30, 2024 | 1.42 Mn |
| Sep 30, 2024 | 1.42 Mn |
| Jun 30, 2024 | 1.20 Mn |
| Jun 30, 2024 | 1.20 Mn |
| Mar 31, 2024 | 1.55 Mn |
| Mar 31, 2024 | 1.55 Mn |